US ‘breakthrough’ badge for MSD/Eisai cancer combo
A combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US.
Read More
Tag: Study 111
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
